lunes, 10 de abril de 2017

Childhood Acute Myeloid Leukemia Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Acute Myeloid Leukemia Treatment (PDQ®)—Health Professional Version - National Cancer Institute



National Cancer Institute

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version





SECTIONS



Changes to This Summary (12/01/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Tawana et al. as reference 17.
Added text to state that in newly diagnosed patients with double-mutant CEPBA acute myeloid leukemia (AML), in addition to usual family history queries, germline screening should be considered, because 5% to 10% of these patients are reported to have a germline CEBPA mutation (cited Tawana et al. as reference 56).
Added text about miR-155 expression in patients with AML (cited Joyce et al., Marcucci et al., and Ramamurthy et al. as references 182, 183, and 184, respectively).
Added text about outcomes associated with induction failure (cited Wells et al., Aplenc et al., and Quarello et al. as references 39, 40, and 41, respectively).
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: December 1, 2016

No hay comentarios:

Publicar un comentario